Clinical Trials Logo

Malignant Melanoma Stage IV clinical trials

View clinical trials related to Malignant Melanoma Stage IV.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05304546 Not yet recruiting - Metastatic Melanoma Clinical Trials

Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma

MK3475-C01
Start date: June 2023
Phase: Phase 2
Study type: Interventional

This study will enroll metastatic (Stage IV or inoperable stage III) melanoma (MM) patients carrying a BRAF V600E/K mutation with confirmed primary resistance to standard of care immunotherapy (single agent PD-1 or a combination of CTLA-4/PD-1 blockade). Patients must be naïve to therapy with BRAF+MEK inhibitors, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

NCT ID: NCT03493230 Not yet recruiting - Clinical trials for Malignant Melanoma Stage IV

Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT )

MALT
Start date: April 2018
Phase: N/A
Study type: Interventional

The main objective of this project is to perform a longitudinal monitoring of BRAF and NRAS cell-free DNA in a large cohort of metastatic melanomas patients before treatment and during the follow-up. Results will be compared with clinical data as imaging (based on RECIST criteria) and the activity of lactate dehydrogenase in serum (LDH).